Ingredients | Amount Per Serving |
---|---|
1000 mg |
Below is general information about the effectiveness of the known ingredients contained in the product Pata de Vaca Powder. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
INSUFFICIENT RELIABLE EVIDENCE to RATE
Below is general information about the safety of the known ingredients contained in the product Pata de Vaca Powder. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
There is insufficient reliable information available about the safety of pata de vaca.
PREGNANCY AND LACTATION:
Insufficient reliable information available; avoid using.
Below is general information about the interactions of the known ingredients contained in the product Pata de Vaca Powder. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
Animal research suggests that pata de vaca may have hypoglycemic effects (27480,27481,27482,27483,27486,27487,27489). However, preliminary clinical research shows that pata de vaca does not reduce blood glucose levels (27471). Until more is known, use with caution. Theoretically, concomitant use of pata de vaca with antidiabetes drugs might affect glucose control and increase the risk of hypoglycemia. Dose adjustments to diabetes medications might be necessary. Some antidiabetes drugs include glimepiride (Amaryl), glyburide (DiaBeta, Glynase PresTab, Micronase), insulin, metformin (Glucophage), pioglitazone (Actos), rosiglitazone (Avandia), and others.
|
Below is general information about the adverse effects of the known ingredients contained in the product Pata de Vaca Powder. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
General ...Orally, no adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.